Understanding FCGR: Potential Drug Target and Biomarker (P22139)

Target Name: Fc-gamma Receptor (FCGR)

NCBI ID: P22139

Fc-gamma Receptor (FCGR)

Other Name(s): None

Understanding FCGR: Potential Drug Target and Biomarker

The Fc-gamma receptor (FCGR), also known as Fc-gamma receptor alpha, is a protein that is expressed in many different tissues throughout the body. It is a member of the G protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a key role in cellular signaling. FCGR is one of the many GPCR family members that has been identified as a potential drug target or biomarker.

FCGR is a type of GPCR that is characterized by its long, N-terminal extracellular domain. This domain is involved in many different functions, including cell adhesion, migration, and signaling. FCGR is also known for its unique ability to form a complex with the protein Fc-gamma (also known as CD71) protein. This complex is called the FCGR-Fc-gamma complex, and it is thought to play a key role in many different cellular processes.

One of the key functions of FCGR is its role in cell signaling. FCGR is involved in a wide range of signaling pathways, including the TGF-beta pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. These pathways are involved in many different cellular processes, including cell growth, differentiation, migration, and inflammation. FCGR is also involved in regulating the activity of many different proteins, including transcription factors, cytokines, and enzymes.

FCGR is also thought to be involved in many different diseases and disorders. For example, FCGR has been identified as a potential drug target for a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Studies have also shown that FCGR is often overexpressed or mutated in many different diseases, which may contribute to its involvement in these conditions.

In addition to its potential as a drug target, FCGR is also a potential biomarker. Because it is involved in many different signaling pathways, FCGR may be able to serve as a useful biomarker for a wide range of diseases. For example, FCGR has been shown to be involved in many different types of cancer, including breast, lung, and colon cancer. It has also been used as a biomarker for a number of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

FCGR is also thought to be involved in many different cellular processes that are important for normal development and function. For example, FCGR is involved in the regulation of cell adhesion, which is important for the development and maintenance of tissues and organs. It is also involved in the regulation of cell migration, which is important for the formation of tissues and organs during development.

In conclusion, FCGR is a protein that is expressed in many different tissues and is involved in a wide range of cellular processes. It is a member of the GPCR family and has been identified as a potential drug target and biomarker for a wide range of diseases . Further research is needed to fully understand the role of FCGR in cellular signaling and its potential as a drug and biomarker.

Protein Name: Fc-gamma Receptor (FCGR) (nonspecified Subtype)

The "Fc-gamma Receptor (FCGR) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Fc-gamma Receptor (FCGR) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets